WallStSmart

agilon health Inc (AGL)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 938% more annual revenue ($60.44B vs $5.82B). AZN leads profitability with a 17.2% profit margin vs -6.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AGL

Hold

37

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 1.54

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AGL.

AZNUndervalued (+8.2%)

Margin of Safety

+8.2%

Fair Value

$194.77

Current Price

$185.95

$8.82 discount

UndervaluedFair: $194.77Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AGL2 strengths · Avg: 9.5/10
EPS GrowthGrowth
301.0%10/10

Earnings expanding 301.0% YoY

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$282.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

AGL4 concerns · Avg: 3.5/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

Market CapQuality
$1.54B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.7%3/10

Operating margin of 0.7%

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AGL

The strongest argument for AGL centers on EPS Growth, Debt/Equity.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bear Case : AGL

The primary concerns for AGL are Price/Book, Altman Z-Score, Market Cap.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

AGL profiles as a turnaround stock while AZN is a mature play — different risk/reward profiles.

AGL carries more volatility with a beta of 2.31 — expect wider price swings.

AZN is growing revenue faster at 12.5% — sustainability is the question.

AZN generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 37/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

agilon health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

agilon health, inc. The company is headquartered in Long Beach, California.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?